These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 30092766)

  • 21. Leptin promotes fatty acid oxidation and OXPHOS via the c-Myc/PGC-1 pathway in cancer cells.
    Liu Q; Sun Y; Fei Z; Yang Z; Duan K; Zi J; Cui Q; Yu M; Xiong W
    Acta Biochim Biophys Sin (Shanghai); 2019 Jul; 51(7):707-714. PubMed ID: 31187140
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Metabolomic Rewiring Promotes Endocrine Therapy Resistance in Breast Cancer.
    Ahn S; Park JH; Grimm SL; Piyarathna DWB; Samanta T; Putluri V; Mezquita D; Fuqua SAW; Putluri N; Coarfa C; Kaipparettu BA
    Cancer Res; 2024 Jan; 84(2):291-304. PubMed ID: 37906431
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CPT1A-mediated fatty acid oxidation confers cancer cell resistance to immune-mediated cytolytic killing.
    Liu Z; Liu W; Wang W; Ma Y; Wang Y; Drum DL; Cai J; Blevins H; Lee E; Shah S; Fisher PB; Wang X; Fang X; Guo C; Wang XY
    Proc Natl Acad Sci U S A; 2023 Sep; 120(39):e2302878120. PubMed ID: 37722058
    [TBL] [Abstract][Full Text] [Related]  

  • 24. iRGD-modified exosomes effectively deliver CPT1A siRNA to colon cancer cells, reversing oxaliplatin resistance by regulating fatty acid oxidation.
    Lin D; Zhang H; Liu R; Deng T; Ning T; Bai M; Yang Y; Zhu K; Wang J; Duan J; Ge S; Sun B; Ying G; Ba Y
    Mol Oncol; 2021 Dec; 15(12):3430-3446. PubMed ID: 34213835
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High Expression of CPT1A Predicts Adverse Outcomes: A Potential Therapeutic Target for Acute Myeloid Leukemia.
    Shi J; Fu H; Jia Z; He K; Fu L; Wang W
    EBioMedicine; 2016 Dec; 14():55-64. PubMed ID: 27916548
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NDRG1 regulates neutral lipid metabolism in breast cancer cells.
    Sevinsky CJ; Khan F; Kokabee L; Darehshouri A; Maddipati KR; Conklin DS
    Breast Cancer Res; 2018 Jun; 20(1):55. PubMed ID: 29898756
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Carnitine palmitoyl transferase 1A is a novel diagnostic and predictive biomarker for breast cancer.
    Tan Z; Zou Y; Zhu M; Luo Z; Wu T; Zheng C; Xie A; Wang H; Fang S; Liu S; Li Y; Lu Z
    BMC Cancer; 2021 Apr; 21(1):409. PubMed ID: 33858374
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting the leukemia cell metabolism by the CPT1a inhibition: functional preclinical effects in leukemias.
    Ricciardi MR; Mirabilii S; Allegretti M; Licchetta R; Calarco A; Torrisi MR; Foà R; Nicolai R; Peluso G; Tafuri A
    Blood; 2015 Oct; 126(16):1925-9. PubMed ID: 26276667
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of macrophage fatty acid β-oxidation exacerbates palmitate-induced inflammatory and endoplasmic reticulum stress responses.
    Namgaladze D; Lips S; Leiker TJ; Murphy RC; Ekroos K; Ferreiros N; Geisslinger G; Brüne B
    Diabetologia; 2014 May; 57(5):1067-77. PubMed ID: 24488024
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CPT1C-mediated fatty acid oxidation facilitates colorectal cancer cell proliferation and metastasis.
    Li J; Zheng W; Wu J; Zhang J; Lv B; Li W; Liu J; Zhang X; Huang T; Luo Z
    Acta Biochim Biophys Sin (Shanghai); 2023 Apr; 55(8):1301-1309. PubMed ID: 37078750
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CPT1A-mediated Fat Oxidation, Mechanisms, and Therapeutic Potential.
    Schlaepfer IR; Joshi M
    Endocrinology; 2020 Feb; 161(2):. PubMed ID: 31900483
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FOXM1 cistrome predicts breast cancer metastatic outcome better than FOXM1 expression levels or tumor proliferation index.
    Yau C; Meyer L; Benz S; Vaske C; Scott G; Egan B; Labhart P; Pourmand N; Benz CC
    Breast Cancer Res Treat; 2015 Nov; 154(1):23-32. PubMed ID: 26456572
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Targeting Fatty Acid Oxidation to Promote Anoikis and Inhibit Ovarian Cancer Progression.
    Sawyer BT; Qamar L; Yamamoto TM; McMellen A; Watson ZL; Richer JK; Behbakht K; Schlaepfer IR; Bitler BG
    Mol Cancer Res; 2020 Jul; 18(7):1088-1098. PubMed ID: 32198139
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Renal tubule Cpt1a overexpression protects from kidney fibrosis by restoring mitochondrial homeostasis.
    Miguel V; Tituaña J; Herrero JI; Herrero L; Serra D; Cuevas P; Barbas C; Puyol DR; Márquez-Expósito L; Ruiz-Ortega M; Castillo C; Sheng X; Susztak K; Ruiz-Canela M; Salas-Salvadó J; González MAM; Ortega S; Ramos R; Lamas S
    J Clin Invest; 2021 Mar; 131(5):. PubMed ID: 33465052
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer.
    Huang D; Chowdhury S; Wang H; Savage SR; Ivey RG; Kennedy JJ; Whiteaker JR; Lin C; Hou X; Oberg AL; Larson MC; Eskandari N; Delisi DA; Gentile S; Huntoon CJ; Voytovich UJ; Shire ZJ; Yu Q; Gygi SP; Hoofnagle AN; Herbert ZT; Lorentzen TD; Calinawan A; Karnitz LM; Weroha SJ; Kaufmann SH; Zhang B; Wang P; Birrer MJ; Paulovich AG
    Cell Rep Med; 2021 Dec; 2(12):100471. PubMed ID: 35028612
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Carnitine-acyltransferase system inhibition, cancer cell death, and prevention of myc-induced lymphomagenesis.
    Pacilli A; Calienni M; Margarucci S; D'Apolito M; Petillo O; Rocchi L; Pasquinelli G; Nicolai R; Koverech A; Calvani M; Peluso G; Montanaro L
    J Natl Cancer Inst; 2013 Apr; 105(7):489-98. PubMed ID: 23486551
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fatty acid oxidation and carnitine palmitoyltransferase I: emerging therapeutic targets in cancer.
    Qu Q; Zeng F; Liu X; Wang QJ; Deng F
    Cell Death Dis; 2016 May; 7(5):e2226. PubMed ID: 27195673
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ADA3 regulates normal and tumor mammary epithelial cell proliferation through c-MYC.
    Griffin NI; Sharma G; Zhao X; Mirza S; Srivastava S; Dave BJ; Aleskandarany M; Rakha E; Mohibi S; Band H; Band V
    Breast Cancer Res; 2016 Nov; 18(1):113. PubMed ID: 27852327
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CPT1A loss disrupts BCAA metabolism to confer therapeutic vulnerability in TP53-mutated liver cancer.
    Liu Y; Wang F; Yan G; Tong Y; Guo W; Li S; Qian Y; Li Q; Shu Y; Zhang L; Zhang Y; Xia Q
    Cancer Lett; 2024 Jul; 595():217006. PubMed ID: 38823763
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Deregulation of MicroRNAs mediated control of carnitine cycle in prostate cancer: molecular basis and pathophysiological consequences.
    Valentino A; Calarco A; Di Salle A; Finicelli M; Crispi S; Calogero RA; Riccardo F; Sciarra A; Gentilucci A; Galderisi U; Margarucci S; Peluso G
    Oncogene; 2017 Oct; 36(43):6030-6040. PubMed ID: 28671672
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.